EC approves ORSERDU® for the treatment of patients with ER+, HER2- locally advanced or metastatic breast cancer with an activating ESR1 mutation.
FLORENCE (Italy) and NEW YORK, NY, September 20, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that the European Commission has…